Recent talk about HIV and aging has almost always been scary. A number of studies conclude that people living with HIV have so-called “accelerated aging”—meaning they will suffer heart attacks, strokes, cancers, and osteoporosis more often and sooner than those without HIV. Well, this is one article on aging and HIV that will challenge the concept of people living with HIV having an early expiration date. Instead, we can look at what we know and what we don’t, to get a better idea of what the risks are for HIV-positive people growing older—and what they can do about them.
08 July 2016 | Positively Aware
Multicenter study preparing for launch, pilot studies already begun
04 July 2016 | MedPage Today
More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.
30 May 2016 | Los Angeles Times
A Birmingham hospital has successfully transplanted two HIV infected organs into patients also suffering from the disease. Liver transplants, from two separate donors, were carried out at the Queen Elizabeth Hospital, in Edgbaston, in the pioneering procedures. Whilst one patient donated both kidneys in surgery performed at Guy’s Hospital, in London.
19 May 2016 | Birmingham Mail
In a first that gives HIV-positive patients yet another chance for long lives, surgeons at Johns Hopkins University Medical Center have transplanted a kidney and a liver from a deceased donor who was positive for HIV into two HIV-positive recipients.
31 March 2016 | Los Angeles Times
Johns Hopkins recently received approval from the United Network for Organ Sharing to be the first hospital in the United States to perform HIV-positive to HIV-positive organ transplants. The institution will be the first in the nation to do an HIV-positive kidney transplant and the first in the world to execute an HIV-positive liver transplant.
09 February 2016 | Johns Hopkins Medicine
In a Federal Register notice on Nov. 25, 2015, the U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection.
27 November 2015 | National Institutes of Health
Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.
12 October 2015 | Monthly Prescribing Reference
A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.
04 September 2015 | HIVandHepatitis.com
The US Department of Health and Human Services (HHS) has unveiled new regulations to establish a parallel system of organ donation intended to serve patients with the human immunodeficiency virus (HIV).
11 May 2015 | Regulatory Affairs Professionals Society